Minimally invasive surgery linked to lower major complication risk, reduced length of stay, decreased transfusion rate.

Cytoreductive nephrectomy merits further consideration in appropriately risk-stratified, surgically fit patients with mRCC.

A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...

Deferred cytoreductive nephrectomy is associated with better survival compared with upfront surgery, including among fit patients receiving immunotherapy. Deferred cytoreductive nephrectomy (CN) may ...

PN and RFA offer similar survival for cT1a RCC tumors ≤2 cm, but PN is superior for larger tumors. RFA may be considered for elderly patients with comorbidities, especially for tumors ≤2 cm. PN ...